ACE2 and chronic kidney disease: Thus, therapies that target the angiotensin-converting enzyme 2 (ACE2)/Angiotensin-(1-7)/Mas receptor (MasR) pathway to prevent cardiovascular events and slow the progression of chronic kidney disease appear to be on the horizon.